METTL3 and hepatocellular carcinoma: METTL3 is found to be significantly decreased in sorafenib-resistant HCC, and depletion of METTL3 under conditions of hypoxia promotes sorafenib tolerance and angiogenic gene expression in HCC cells and activates autophagy-related pathways (Lin et al., 2020b).